GILD · News · 20261104N

Oncology Pipeline Progress

GILEAD SCIENCES, INC. · 2026-11-04 · Importance 17 · Surprise 24

Gilead and Kite announced 23 presentations, including seven oral presentations, for the December 12–15, 2026 American Society of Hematology meeting. Planned data include at least 18 months of follow-up on anito-cel’s durability and safety in relapsed or refractory multiple myeloma, and five-year follow-up for Yescarta in first-line high-risk large B-cell lymphoma. The company also cited early clinical results for approaches in lymphoma and autoimmune blood disorders.

Key facts

• Gilead Sciences announced a clinical trial collaboration with BioNTech to test BioNTech's bispecific immunomodulator pumitamig combined with a Gilead antibody-drug conjugate in a global Phase 3 study for metastatic triple-negative breast cancer. source
• Gilead Sciences and Kite announced 23 presentations, including 7 oral presentations, at the 68th American Society of Hematology Annual Meeting and Exposition, scheduled for December 12–15, 2026. source
• Gilead and Kite reported anito-cel data with a minimum of 18 months of follow-up on durability and safety in relapsed or refractory multiple myeloma. source
• Gilead and Kite reported five-year ZUMA-12 follow-up data for Yescarta in first-line high-risk large B-cell lymphoma. source